Clinical Outcomes Associated with NPM1 Mutations in Patients with Relapsed or Refractory AML

Scientists identified 206 patients with mutated Nucleophosmin 1 (NPM1) and compared their outcomes to 1516 patients with NPM1 wild-type. It was found that NPM1 mutational status had minimal impact on prognosis in relapsed or refractory AML.